Restricted Research - Award List, Note/Discussion Page
Fiscal Year: 2023
332 The University of Texas Rio Grande Valley (142220)
Principal Investigator: Chauhan,Subhash C
Total Amount of Contract, Award, or Gift (Annual before 2011): $ 64,000
Exceeds $250,000 (Is it flagged?): No
Start and End Dates: 7/1/23 - 6/30/24
Restricted Research: YES
Academic Discipline: Immunology and Microbiology
Department, Center, School, or Institute: Immunology and Microbiology
Title of Contract, Award, or Gift: Generation of Novel CAR-T Therapy for Pancreatic Cancer
Name of Granting or Contracting Agency/Entity:
Kosten Foundation Pancreatic Cancer Rese
CFDA: n/a
Program Title: n/a
Note:
SAMs 1.1.1--Pancreatic Ductal Adenocarcinoma (PDAC) patients with metastatic disease exhibit extremely poor prognosis with approximately 6 months overall survival, as PDAC is largely refractory to conventional therapies. It is shown that PDAC tumors typically represent with severe genetic level heterogeneity along with the large number cancer stem cell (CSC) population. These factors in association contribute to therapy failure, disease recurrence and disease progression. At present time, existing therapies at the best extend survival by few months only, therefore, the development of newer therapies is urgently needed to improve the PDAC treatment. Certainly, this is an unmet clinical need in the field of PDAC. CAR-T cells have shown remarkable efficacy for the treatment of soft and liquid malignancies, but in solid tumors, especially in PDAC, it showed only limited success thus far. A major challenge in this respect is the lack of an ideal CAR-T target antigens that is strongly expressed on malignant cells, while lacking/or very low on normal tissues to avoid off target toxicities. Our lab delineated the oncogenic role of MUC13 in pancreatic cancer (PanCa) that MUC13 can be a unique therapeutic/diagnostic target for PanCa. Thus, we have generated unique anti-MUC13 mouse monoclonal (MAb) and recombinant humanized (HuAb) antibodies that can efficiently target pancreatic tumors.
Discussion: No discussion notes